annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 51A Relation between baseline LDH and tumor burden in advanced melanoma in
two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC.
(Abstract #8557)
C. Lebbé, J. J. Grob, A. Y. Bedikian, C. Garbe, C. Robert, L. Itri, J. Wu,
S. S. Agarwala, A. M. Eggermont
Brd. 51B MGMT promoter methylation status in metastatic melanoma patients
receiving first-line temozolomide plus bevacizumab (SAKK 50/07).
(Abstract #8558)
A. F. Ochsenbein, P. Schraml, D. Mihic, M. Simcock, R. Dummer, O. Michielin,
B. Seifert, M. R. Schlaeppi, H. Moch, R. von Moos, SAKK
Brd. 51C Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4720:
The key to therapeutic success? (Abstract #8559)
P. Hersey, X. Zhang, C. Jiang
Brd. 51D Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant
sargramostim (GM-CSF) in patients with advanced melanoma. (Abstract
#8560)
J. Lutzky, D. H. Lawson, Y. Enriquez-Nunez, D. Gabrilovich
Brd. 51E Oblimersen 1-hour IV infusion in combination with temozolomide and
albumin-bound paclitaxel in patients with advanced melanoma.
(Abstract #8561)
P. A. Ott, K. M. Madden, R. Kannan, H. Yee, S. Mendoza, B. Dubose, L. Liebes,
A. C. Pavlick
Brd. 51F Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in
metastatic melanoma. (Abstract #8562)
T. Gajewski, Y. Zha, J. Clark
Brd. 51G The impact of physician specialty on quality of melanoma care. (Abstract
#8563)
J. N. Cormier, Y. T. Shih, Y. Xu, I. Pan, R. L. Askew, M. I. Ross, J. E. Gershenwald,
J. E. Lee, R. Royal, Y. Xing
Brd. 51H Durable response of the triple combination of temozolomide, sorafenib, and
bevacizumab to treat refractory stage IV acral melanoma. (Abstract #8564)
L. Si, M. Han, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, Y. Kong, J. Guo
Brd. 52A CD20-immunotargeting of malignant melanoma. (Abstract #8565)
S. N. Wagner, R. Somasundaram, A. Pinc, P. A. Van Belle, C. Wagner,
M. Hoermann, G. Karanikas, G. Stingl, D. Elder, M. Herlyn
Brd. 52B Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and
ultraviolet light. (Abstract #8566)
H. E. Kanavy, M. A. Warycha, H. Hamilton, A. Souza, I. Osman, L. Chiriboga,
H. Yee, N. Soter, B. Strober, D. Polsky
Brd. 52C Changes in regional immunity and metastasis in melanoma. (Abstract #8567)
A. S. Mansfield, T. Grotz, J. W. Jakub, T. Flotte, L. Erickson, S. Markovic
Brd. 52D Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in
dendritic cells through IL-10, STAT3, and p38-dependent pathways and on
antimelanoma CD8� T-cell priming. (Abstract #8568)
D. Bogunovic, O. Manches, A. Yewdall, I. Marie, D. E. Levy, N. Bhardwaj
Brd. 52E Interleukin-2-induced fever in relation to objective tumor response and
survival in patients with metastatic melanoma. (Abstract #8569)
M. Ellegaard, L. Bastholt, A. Jakobsen, F. Donskov, H. Schmidt
Brd. 52F Identification of tyrosinase polymorphisms for use in melanoma risk
assessment. (Abstract #8570)
E. Pervolaraki, I. Lobach, I. Belitskaya-Levy, H. Ostrer, J. D. Goldberg, D. Polsky,
R. L. Shapiro, R. S. Berman, I. Osman, P. Manga
Brd. 52G Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
(Abstract #8571)
A. C. Pavlick, P. A. Ott, R. Kannan, K. M. Madden, C. Sorlie, C. Escano,
J. Escalon, E. Hernando-Monge, I. Osman, N. Bhardwaj
225
SUNDAY